

Behavioral Health Committee Meeting

NPAIHB QBM July 27-29, 2021

07/27/2021

Facilitator: Dr. Danica Love Brown

Notes: Karin Dean

Attendees (12):

Caroline Cruz, Confederated Tribes of Warm Springs
Mia Red Crow, Spokane Tribe (Youth Delegate)
Maiya Martinez, Spokane Tribe (Youth Delegate)
Dr. Obinna Oleribe, Klamath Tribes
John Okemah, Tulalip Tribes
Darryl Scott, Confederated Tribes of Warm Springs
Marilyn Scott, Upper Skagit Indian Tribe
Veronica Smith, Lummi Nation
Sharon Stanphill, Cow Creek Band of Umpqua Indians
Kaela Tyler, Makah (Youth Delegate)
Nate Tyler, Makah Tribe
Libby Watanabe, Snoqualmie Tribe

NPAIHB Staff/Assignees (14):

Danica Love Brown, Behavioral Health Director
Bridget Canniff, IP & PHIT Project Director
Colbie Caughlan, TOR, THRIVE, and RC Project Director
Stephanie Craig Rushing, Adolescent Health Project Director
Karin Dean, Behavioral Health Coordinator
Tanya Firemoon, TCHPP Specialist
Valerie Gaede, PHIT Project Assistant
Melino Gianotti, OR Public Health Analyst
Barbara Gladue, OR Tribal Public Health Improvement Manager
Ashley Hoover, Communicable Disease Epidemiologist
Candice Jimenez, Health Policy Specialist
Larissa Molina, TOR Project Specialist
Victoria Warren-Mears, Tribal EpiCenter Director
Birdie Wermey, Behavioral Health Manager

Blessing

Roll Call

Project Updates

Danica Love Brown, Behavioral Health Director:

- Behavioral Health ECHO virtual clinics
 - BH ECHO virtual clinics are held the 4th Thursday of the month
 - The next BH ECHO virtual clinic is scheduled for August 26, 2021 at 12:00pm
 - More information (including past clinics and registration for upcoming clinics) can be found at <https://www.indiancountryecho.org/program/behavioral-health-echo>
 - Future BH ECHO clinics planned to focus on Elders and Knowledge Keepers
- Behavioral Health Trainings
 - “Coping and Caring for Yourself and Others” training series
 - Started at the beginning of June
 - Held on the 1st and 3rd Wednesdays of the month at 12:00pm
 - Class descriptions on [Flyer](#)
 - Eight 1-hour classes over 4 months, includes Continuing Education and coping skills from Dialectical Behavior Therapy
 - Register twice (classes are first for the [first Wednesdays](#) and second for the [third Wednesdays](#) of the month at 12pm Pacific)
 - In collaboration with Dr. Ursula Whiteside, clinical faculty at the University of Washington and founder of www.nowmattersnow.org
 - “Caring for Elders in Our Community” webinar
 - August 19, 2021 at 12:00pm
 - In collaboration with Kauffman & Associates, Inc. (KAI) (www.kauffmaninc.com)

- Behavioral Health Aide Clinical Supervision Workgroup
 - Establishing a workgroup in Washington with Dr. Jeff King (Clinical Supervisor)
 - An Oregon workgroup will also be started when a state Clinical Supervisor is chosen
 - Goals are to increase/improve engagement with tribes and develop long-term plans
- Behavioral Health Aide Program Updates
 - Education Programs (including curriculum) are being established with both the Heritage University Social Work Department and the Northwest Indian College
 - Will include guidance and input from Elders and Knowledge Keepers
 - 3 different pathways to certification are currently being developed, including:
 - Associates Degree (AA) in Chemical Dependency
 - Bachelor of Social Work
 - Behavioral Health Aide/Practitioner certifications
 - Future plans for Peer Recovery Specialists are also being considered
- 49 Days of Ceremony
 - The framework/model will be completed by end of 2021
 - An Alaska tribe will pilot the program in 2022
 - A Washington tribe will be selected to pilot the program after outreach efforts are conducted this fall
 - Long-term goals including securing funding from IHS for 5 or more years and expand the program to other PNW tribes
- Staffing Updates
 - New staff member Karin Dean (BH Program Coordinator); kdean@npaihb.org
 - Currently recruiting for the newly created position of Behavioral Health Aide Program Director (<https://www.npaihb.org/careers>)

Tanya Firemoon, TCHPP Specialist:

- 2nd Annual Gathering of Northwest Elders, Knowledge Holders, & Culture Keepers virtual seminar was held on June 29-30, 2021 (BHA-related event; see <https://www.tchpp.org/behavioralhealthaideprogram> for more information)
- Carrie Sampson-Samuels (CHAP Director) presentation this Thursday (July 29, 2021) at 9:45am for the QBM
- Presenting at the August 19, 2021 BH training (“Caring for Elders in Our Community”)

Colbie Caughlan, Behavioral Health Manager:

- Tribal Opioid Response (TOR)
 - 1st year cohort of TOR grantee funds expire on September 29, 2021
 - 2nd year cohort of TOR grantee funding extends into the 2022 fiscal year, which begins September 30, 2021
 - 3rd year cohort is still in its first year of funding
 - 4th year cohort is TBD, with an update expected anywhere from late August to mid-September
 - SAHMSA Region 10 Opioid Summit will be held (virtually) August 3-5, 2021 (<https://region10opioidsummit.org>)
- THRIVE Suicide Prevention Project
 - 3 tribes have almost fully implemented the THRIVE action plan
 - Crisis texting lines
 - Text lines are 988, 97779, and 65664
 - College students receive caring text messages
 - Veterans text line planned for launch on Veteran’s Day (keyword TBD)

Candice Jimenez, Health Policy Specialist:

- Opioid Response Learning Collaborative Region 10 Annual Meeting is on August 2, 2021 (<https://www.orlcmeeting.com>)
- Accepting written statements/priorities from tribes for the SAHMSA Tribal Advisory Committee (joint with IHS National Tribal Advisory Committee on Behavioral Health) meeting next week on August 3-4, 2021
 - Send comments in an email to cjimenez@npaihb.org

Stephanie Craig Rushing, Adolescent Health Projects Director:

- We R Native website has had new content developed around mental health challenges and building resilience (including trauma, self-care, and other topics) and sexual health/healthy relationships (<https://www.wernative.org/my-mind>)
- Youth can use the website to sign up for “caring text messages” for topics such as identity and cultural pride

Victoria Warren-Mears, Tribal EpiCenter Director

- 5 Year continuation application is due this fall
 - Will need to request letters of support from tribes with a quick (30 day or less) turnaround
 - Exact dates TBD, but expected in September or October
 - Wishes to thank delegates in advance for assistance and flexibility with the process
- Holding a youth art contest in partnership with NIDA which goes through the end of December (<https://www.wernative.org/contest>)
 - Youth are invited to develop plans for a project that they believe would augment resilience to substance use in communities, submitting a plan for the project and a video description
 - Prizes are \$2,000-\$10,000 per entry, with a total amount of \$85,000 to be awarded

Tribal Updates

Marilyn Scott, Upper Skagit Indian Tribe

- Concerns about a significant recent increase in fentanyl-related overdoses, as well as an associated increase in the use of Narcan es (i.e., reports of needing to use 8 or more doses of Narcan to treat overdose)
- Increase in fentanyl-related overdoses caused by both an increase in availability of fentanyl in general, as well as lacing with other drugs (such as heroin, prescription opiates, or meth)
- Suggests alleviating the problem by improving access to Narcan within the community (such as first responders or friends/family members) and having enough stock to distribute
- Also expressed concern around the use of expired Narcan
 - Colbie’s Response:
 - Kits of 300 doses of Narcan were sent to tribes in April
 - Would also benefit from outreach/education on the need for higher doses to combat overdose
 - If tribes are experiencing delays in obtaining Narcan from pharmaceutical companies, they can email Larissa, Colbie, or Eric (lmolina@npaih.org, ccaughlan@npaih.org, evinson@npaih.org)
 - if you have NARCAN with a 2020 expiration date, it is probably still good through 2021, most expirations added another 12mo to them last year
 - Danica’s Response:
 - A current vendor producing Narcan recently changed its name from Adapt Pharma to Emergent Devices, so hopefully knowing this will prevent any confusion if you see both names moving forward
 - Company Contact info:
 - Phone: (844) 232-7811
 - narcancustomerservice@ebsi.com
 - Contact information for our new account representative is:
 - Timothy Yabor
 - Phone: (484) 253-3027
 - yabort@ebsi.com
 - Timothy has been very helpful and the person you will contact to set-up your account
 - Send him completed form (Terms & Conditions, Credit Application) once filled out and signed (*see file attachments*)
 - There is a Washington State Standing Order that allows you to have Narcan shipped directly to you without a provider signature (*see file attachments*)
 - If they’re not in Washington state they’ll need a prescriber to fill out the LOA form

Veronica Smith, Lummi Nation

- There is a stronger version of Narcan that is currently being developed, but not yet available
- A youth drug prevention planning summit is in the works

Caroline Cruz, Confederated Tribes of Warm Springs

- A satellite center for the suicide hotline program, Lines for Life, recently opened in Warm Springs
- A new collaborative software, CareDocs, has recently been implemented in the behavioral health center, and will eventually be used throughout the department
- The software is compatible with RPMS, works with billing codes, and will allow patients to access and monitor their own medical records and treatment plans
- Recently opened a cooling center in response to the extreme heat which is currently serving as more of a homeless shelter
- Purchased 7 FEMA trailers to be used for COVID-19 quarantine locations, which will later be used as transitional homes
- 10 studio cottages are being constructed, which will be used to move some of the individuals experiencing houselessness with the assistance of the Behavioral Health Program
- An existing school cafeteria that is currently unused will be converted into a wellbriety community center
- SB755 passed recently and decriminalized psilocybin, so they now have plans to manufacture and sell it
- SB 988 also passed, which creates a mental health hotline
- Hosted a tribal youth opioid academy this past spring, and next May it will be hosted by Cow Creek (including a silent auction with proceeds going to MMIW) in Canyonville at Seven Feathers Resort
- Had two conferences recent (one on Grief, another was a youth cultural camp), and both had good attendance (around 70-100 people) and thankfully no COVID-19 cases due to masking/social distancing
 - Colbie's Response:
 - Suggests they reach out directly to allow us to help them acquire more funding for the suicide hotline project

Requests from BH Committee

Danica Love Brown, Behavioral Health Director:

- Boarding School Healing Project (new proposal): how can we support needs around this emerging concern?
 - Caroline's Response:
 - Will look how to honor at the upcoming tribal youth opioid academy
 - Marilyn's Response:
 - Would like it to include historical trauma considerations
 - Nate's Response:
 - Acknowledges that this is a newer issue in general facing the U.S., and presents an opportunity for us to take timely action

Needs/Requests/Follow-up

- Karin will send out save-the-date flyers for the upcoming "Caring for Elders in Our Community" webinar training on August 5, 2021
- Danica will send out an email about the BHA Clinical Supervision Workgroup
- Colbie will send out an update about the 4th year of TOR grants as soon as we receive that information
- Candice will send out more information about written statements needed for next week's joint SAHMSA/IHS Tribal Behavioral Health Advisory Committee
- Victoria will reach out when we get more information about letters of support needed from tribes for the upcoming 5 year continuation application (including dates and timeline)

Narcan[®] Nasal Spray at Public Interest Price Terms and Conditions

The undersigned (“Customer”) hereby acknowledges and agrees that NARCAN[®] Nasal Spray (Naloxone HCl) 4mg (the “Product”) made available by Adapt Pharma, Inc. (“Adapt Pharma”) to Customer at the Public Interest Price is conditioned upon Customer making the following certification (“Certification”). Customer hereby represents and warrants to Adapt Pharma and agrees as follows:

1. Customer is a Qualified Purchaser of the Product at the Public Interest Price. A “Qualified Purchaser” means (a) a First Responder, State or Local Government Agency, School, Community-based organization, (b) a government funded organization, (c) an entity that has received a grant for the purchase of the Product, or (d) an entity that is purchasing the Product on behalf of a government entity or community members by acting as a naloxone distribution program or community based organization. Notwithstanding the foregoing, Customer shall be subject to Adapt Pharma’s final approval in its sole discretion.
2. Customer shall purchase, receive and use the Product in accordance with all applicable laws, rules and regulations. Customer has presented to Adapt Pharma a valid pharmacy license or standing order for purchase and use of the Product. The Product may only be used by Customer, or a Qualified Purchaser authorized by Customer, and may not be submitted for reimbursement of any type, including, without limitation, private pay, commercial, government authority, agency or otherwise.
3. The Product is not returnable or refundable. Minimum order quantity is 12 units (1 case).
4. An invoice will be sent to Customer at its billing address. Unless otherwise specified on the invoice, all invoices for Product supplied are payable in full within thirty (30) days from the date of invoice. Customer agrees to review invoices upon receipt and to notify Adapt Pharma in writing of any disputes within twenty (20) days of receipt of invoice. If such written notice is not received by Adapt Pharma, the invoice will be deemed to be final and payable in full.
5. Adapt Pharma shall have the right and is authorized to request information from Customer and third parties to confirm Qualified Purchaser status and/or credit status prior to accepting an order, and Customer shall fully cooperate with any such request.
6. Adapt Pharma reserves the right to audit Customer to ensure the Product is used as set forth in this Certification and as otherwise required by Adapt Pharma.
7. All orders are subject to acceptance by Adapt Pharma. Adapt Pharma may fulfill or refuse or otherwise limit orders at its sole discretion. Adapt Pharma shall use reasonable efforts to supply Customer with Product; provided, however, that Adapt Pharma shall have no liability for failure to supply Product.
8. All of the information provided by the Qualified Purchaser is true, complete and accurate.
9. Adapt Pharma warrants that at the time of delivery, the Product (a) shall be free from any defects in design, material, or workmanship, (b) shall not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act, and (c) shall conform to laws, rules and regulations of the FDA. In the event that the Product delivered to Customer fails to conform to the warranties in this paragraph, Customer may reject such Product by giving written notice within thirty (30) days after delivery. If Customer fails to reject the Product in accordance with this paragraph within the thirty (30) day period, Customer shall be deemed to have accepted the shipment. ADAPT PHARMA MAKES NO OTHER WARRANTIES, WHETHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE PRODUCT, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.
10. Adapt Pharma’s sole obligation under any warranty shall be to replace or refund defective Products. NEITHER CUSTOMER NOR ADAPT PHARMA SHALL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES OR LOSSES, INCLUDING LOST PROFITS, EVEN IF ADVISED OF THE POSSIBILITY THEREOF.
11. Customer has reviewed, and Customer has provided Qualified Recipients authorized by Customer to receive and/or administer the Product, the instructions for use, storage, handling, and other information with respect to the Product in accordance with the FDA approved prescribing information, and Customer and such Qualified Recipients will comply with such instructions and information. Customer shall be responsible for the negligent acts and omissions of its employees, agents, and representatives.
12. The term of this Certification shall commence on the date of this Certification and continue for a period of one (1) year thereafter (“Term”). The expiration or termination of this Certification shall not release Customer from fulfilling any obligations it may have incurred prior to any such termination, nor prejudice any rights or remedies that Adapt Pharma may have at law or in equity.
13. During the Term and for a period of one (1) year thereafter, Customer shall hold the terms of this Certification and information Adapt Pharma discloses to Customer in confidence and not use or disclose it to any third party without the written consent of Adapt Pharma.
14. This Certification and Customer’s credit application delivered to Adapt Pharma, constitute the entire agreement and understanding of the parties with respect to the subject matter hereof. No changes to this Certification will be binding upon Adapt Pharma unless made in writing and signed by Adapt Pharma. In the event of any conflict between this Certification and any other agreement or purchase order of Customer, this Certification shall govern.
15. Failure of Adapt Pharma to enforce a right does not waive it. If a court of competent jurisdiction finds that any provision of this Certification is invalid or unenforceable, the other provisions of this Certification will remain in full force and effect.

16. Adapt Pharma shall not be liable for delay or failure of performance occasioned by causes beyond its control, including, but not limited to, acts of God, civil unrest, acts of terrorism, declared or undeclared wars, fires, floods, unusually severe weather, earthquakes, strike, lock-out, or other industrial or transportation disturbance, governmental law, regulation or ordinance, failure of public utilities, or unavailability, shortage or interruption of ingredients, raw materials, packaging and/or other materials.
17. Customer may not assign any rights, interests or obligation hereunder without the prior written consent of Adapt Pharma. Adapt Pharma and Customer will at all times be independent contractors. This Certification will not be interpreted or construed to create an association, joint venture or partnership between the parties or to impose any partnership obligation or liability upon either party.

ACKNOWLEDGED AND AGREED:

Customer Full Legal Name

Signature

Name of Authorized Representative

Title

Type of Qualified Entity (please select from list above)

Address

Date:

Organization/Entity:

Address:

City: State: Zip Code:

Date (MM/DD/YYYY): / /

This form can be returned by clicking the "Submit Form" button at the top-right of this page.

This may also be returned via email (narcancustomerservice@ebsi.com) or fax (484-367-7815).

Emergent Devices Inc (formerly known as Adapt Pharma Inc) - Specialty Pharm Services
ATTN: Customer Service
15 Ingram Blvd.
Lavergne, TN 37086

Name of Licensed Prescriber

I,

am the responsible person for purchases made by

Organization/Entity Name

Organization/Entity Address

State License Number

State Initials

under my state license number issued by the State of .

If shipments will be made to multiple locations, please list all names and addresses below:

Please feel free to submit a supplemental document or spreadsheet with the additional shipping addresses if preferred

I will notify Emergent Devices Inc (formerly known as Adapt Pharma Inc) - Specialty Pharm Services immediately if my responsibility status and/or relationship with this facility is changed or terminated.

Prescriber's Signature



STANDING ORDER TO DISPENSE NALOXONE

Authority: This standing order is issued in accordance with RCW 69.41.095(5), which allows for “[t]he secretary or the secretary’s designee [to] issue a standing order prescribing opioid overdose reversal medications to any person at risk of experiencing an opioid-related overdose or any person or entity in a position to assist a person at risk of experiencing an opioid-related overdose.”

The physician issuing this standing order has been designated to do so by the Secretary of Health.

Purpose: The purpose of this standing order is to aid persons experiencing an opioid related overdose by facilitating distribution of the opioid antagonist naloxone to people in Washington.

Authorization: This standing order shall be considered a naloxone prescription for an eligible person or entity. This standing order authorizes a pharmacist to dispense naloxone to any eligible person or entity. This standing order authorizes any eligible person or entity in the State of Washington, including but not limited to any wholesaler licensed in the State of Washington, to possess, store, deliver, distribute, or administer naloxone.

An eligible person or entity is any person at risk of experiencing an opioid-related overdose or any person or entity in a position to assist a person at risk of experiencing an opioid-related overdose. These could include a natural person, such as an individual at risk of an opioid-related overdose or a family member, friend or acquaintance of that individual; or a legal person, such as an ambulance service, police department, or school or other educational institution that could be in a position to assist a person at risk of experiencing an opioid-related overdose.

Terms and Conditions: Any pharmacist dispensing naloxone to eligible persons or entities, as defined above, must provide written instructions on the proper response to an opioid-related overdose, including instructions for seeking immediate medical attention.

Pharmacists using this standing order to dispense naloxone should list the provider who signed this order as the prescriber.

Any individual or entity that dispenses, distributes, or delivers an opioid overdose reversal medication as authorized by this section shall ensure that directions for use are provided. Pharmacies and other entities are strongly encouraged to provide in-person training and allow hands-on practice with a demonstration kit and/or show a training video to persons receiving naloxone for the first time. Training may include information on the proper response to an opioid-related overdose; instructions on the role of naloxone; recognizing a potential opioid-related overdose; verifying unresponsiveness; calling 911; administering naloxone; starting rescue breathing; administering a second dose of naloxone if needed; and providing post-overdose care.

Written printable instructions and a training video for lay persons on responding to an opioid-related overdose and administering naloxone are available at:

<https://www.doh.wa.gov/YouandYourFamily/DrugUserHealth/OverdoseandNaloxone/NaloxoneInstructions>

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

Naloxone HCL Dispensing Procedures

Pharmacies and other entities can dispense and deliver the following naloxone products to eligible persons and entities based on availability and preference. Eligible persons and entities include persons at risk of experiencing an opioid-related overdose or persons or entities in a position to aid persons experiencing an opioid-related overdose.

Intramuscular Naloxone Hydrochloride Injection Solution (0.4 mg/ml)

Dispense: **Two or more** 1ml single dose vials of naloxone HCL (0.4mg/1ml) inj. and **sufficient quantity of** 3 ml syringes with 23 or 25 gauge 1.5" needles for the number of doses dispensed.

Directions for use: Call 911. Inject the entire solution of the vial intramuscularly in the shoulder or thigh. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.

NARCAN Nasal Spray (4mg/0.1 ml)

Dispense: **Two or more** NARCAN® 4mg nasal sprays.

Directions for use: Call 911. Administer a single spray of NARCAN® in one nostril. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.

Generic Naloxone Hydrochloride Nasal Spray (4mg/0.1ml)

Dispense: **Two or more** generic naloxone HCl 4mg nasal sprays.

Directions for use: Call 911. Administer a single spray in one nostril. Repeat after two to three minutes as needed if no or minimal response.


Refills: As needed.

Evzio® Naloxone HCl Injection, USP auto-injector (2mg)

Dispense: **Two or more** Evzio® 2mg auto-injector devices and 1 trainer device.

Directions for use: Remove auto-injector device from outer case. Remove red safety cover on bottom of device. Place black end of device firmly against person's thigh. Press firmly and listen as device counts down from 3 to 1. Once the device gives approval, remove device from thigh. Repeat after two to three minutes as needed if no or minimal response.

Refills: As needed.



MD 00033520

02/01/2021

Physician Signature and License No.**Date**

Scott Lindquist, MD, MPH

NPI 1780611871

Physician Name (Printed)**Expiration, Renewal and Review**

This standing order will automatically expire on 02/01/2023 or on the date that the physician who signed the order revokes it or ceases to act as the Secretary of Health's designee, whichever comes sooner. This standing order shall be reviewed on a regular basis against current best practices and may be revised or updated if new information about naloxone administration necessitates it.